Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Trial watch: IDO inhibitors in cancer therapy.

Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 15;3(10):e957994. eCollection 2014 Nov. Review.

2.

The use of radiotherapy in the management of follicular cystitis refractory to conservative and surgical management.

Trombetta M, Packard M, Ferrara D, Werts ED.

Rare Tumors. 2012 Apr 12;4(2):e25. doi: 10.4081/rt.2012.e25. Epub 2012 May 18.

3.

Tumor-cell co-culture induced alternative activation of macrophages is modulated by interferons in vitro.

Müller-Quernheim UC, Potthast L, Müller-Quernheim J, Zissel G.

J Interferon Cytokine Res. 2012 Apr;32(4):169-77. doi: 10.1089/jir.2011.0020. Epub 2012 Jan 26.

4.

Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.

Luo Y, Henning J, O'Donnell MA.

Clin Dev Immunol. 2011;2011:728930. doi: 10.1155/2011/728930. Epub 2011 Sep 15. Review.

5.

The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.

Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, Wick W, Platten M.

PLoS One. 2011;6(5):e19823. doi: 10.1371/journal.pone.0019823. Epub 2011 May 20.

6.

Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas.

Cathro HP, Smolkin ME, Theodorescu D, Jo VY, Ferrone S, Frierson HF Jr.

Cancer Immunol Immunother. 2010 Mar;59(3):465-72. doi: 10.1007/s00262-009-0765-9. Epub 2009 Sep 16.

7.

Immune cell recruitment and cell-based system for cancer therapy.

Gao JQ, Okada N, Mayumi T, Nakagawa S.

Pharm Res. 2008 Apr;25(4):752-68. Epub 2007 Sep 22. Review.

Supplemental Content

Support Center